Salbutamol + Ipratropium BromideThird Party Manufacturing in India

Salbutamol + Ipratropium Bromide works by utilizing two distinct pathways to maximize bronchodilation in the airways. Salbutamol acts as a short-acting beta2-adrenergic receptor agonist that relaxes airway smooth muscle by stimulating intracellular adenyl cyclase, which increases cyclic AMP levels. Concurrently, ipratropium bromide acts as an anticholinergic agent by blocking muscarinic receptors on smooth muscle, thereby inhibiting vagally-mediated bronchoconstriction. This dual mechanism provides superior efficacy compared to either drug used alone, making Salbutamol + Ipratropium Bromide third party manufacturing in India highly sought after by commercial distributors. This combination represents an optimal respiratory therapy that is well-tolerated and rapidly effective. The primary active component, salbutamol, tracks under CAS number 18559-94-9 to ensure standard verification across markets.

Therapeutic Uses

• Chronic Obstructive Pulmonary Disease: Used for the management of reversible bronchospasm associated with chronic obstructive pulmonary disease.
• Acute Asthma Exacerbations: Provides rapid relief of acute bronchospasm during asthma flare-ups.

Why Manufacturers Choose Salbutamol + Ipratropium Bromide

Celesta Healthcare delivers exceptional access to top-tier respiratory formulations through established networks. Our partner facilities are WHO-GMP certified, ensuring adherence to global regulatory quality standards. This product is a staple in corporate portfolios, making Salbutamol + Ipratropium Bromide third party manufacturer in India a highly profitable collaboration choice.